275 related articles for article (PubMed ID: 24649818)
1. Cancer diagnostic classifiers based on quantitative DNA methylation.
Lorincz AT
Expert Rev Mol Diagn; 2014 Apr; 14(3):293-305. PubMed ID: 24649818
[TBL] [Abstract][Full Text] [Related]
2. Virtues and Weaknesses of DNA Methylation as a Test for Cervical Cancer Prevention.
Lorincz AT
Acta Cytol; 2016; 60(6):501-512. PubMed ID: 27806357
[TBL] [Abstract][Full Text] [Related]
3. Early Epigenetic Markers for Precision Medicine.
Dumitrescu RG
Methods Mol Biol; 2018; 1856():3-17. PubMed ID: 30178243
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic targets in the diagnosis and treatment of prostate cancer.
Manoharan M; Ramachandran K; Soloway MS; Singal R
Int Braz J Urol; 2007; 33(1):11-8. PubMed ID: 17335593
[TBL] [Abstract][Full Text] [Related]
5. The importance of DNA methylation in prostate cancer development.
Massie CE; Mills IG; Lynch AG
J Steroid Biochem Mol Biol; 2017 Feb; 166():1-15. PubMed ID: 27117390
[TBL] [Abstract][Full Text] [Related]
6. A urine-based DNA methylation assay, ProCUrE, to identify clinically significant prostate cancer.
Zhao F; Olkhov-Mitsel E; Kamdar S; Jeyapala R; Garcia J; Hurst R; Hanna MY; Mills R; Tuzova AV; O'Reilly E; Kelly S; Cooper C; ; Brewer D; Perry AS; Clark J; Fleshner N; Bapat B
Clin Epigenetics; 2018 Nov; 10(1):147. PubMed ID: 30470249
[TBL] [Abstract][Full Text] [Related]
7. The expanding role of epigenetics in the development, diagnosis and treatment of prostate cancer and benign prostatic hyperplasia.
Dobosy JR; Roberts JL; Fu VX; Jarrard DF
J Urol; 2007 Mar; 177(3):822-31. PubMed ID: 17296351
[TBL] [Abstract][Full Text] [Related]
8. Validation of an epigenetic field of susceptibility to detect significant prostate cancer from non-tumor biopsies.
Yang B; Etheridge T; McCormick J; Schultz A; Khemees TA; Damaschke N; Leverson G; Woo K; Sonn GA; Klein EA; Fumo M; Huang W; Jarrard DF
Clin Epigenetics; 2019 Nov; 11(1):168. PubMed ID: 31779677
[TBL] [Abstract][Full Text] [Related]
9. Epigenetic biomarkers in prostate cancer: Current and future uses.
Chiam K; Ricciardelli C; Bianco-Miotto T
Cancer Lett; 2014 Jan; 342(2):248-56. PubMed ID: 22391123
[TBL] [Abstract][Full Text] [Related]
10. The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications.
Blute ML; Damaschke NA; Jarrard DF
Curr Opin Urol; 2015 Jan; 25(1):83-8. PubMed ID: 25405932
[TBL] [Abstract][Full Text] [Related]
11. Identification of novel tumor markers in prostate, colon and breast cancer by unbiased methylation profiling.
Chung W; Kwabi-Addo B; Ittmann M; Jelinek J; Shen L; Yu Y; Issa JP
PLoS One; 2008 Apr; 3(4):e2079. PubMed ID: 18446232
[TBL] [Abstract][Full Text] [Related]
12. DNA Methylation-Based Testing in Liquid Biopsies as Detection and Prognostic Biomarkers for the Four Major Cancer Types.
Constâncio V; Nunes SP; Henrique R; Jerónimo C
Cells; 2020 Mar; 9(3):. PubMed ID: 32150897
[TBL] [Abstract][Full Text] [Related]
13. Methylomics analysis identifies epigenetically silenced genes and implies an activation of β-catenin signaling in cervical cancer.
Chen YC; Huang RL; Huang YK; Liao YP; Su PH; Wang HC; Chang CC; Lin YW; Yu MH; Chu TY; Lai HC
Int J Cancer; 2014 Jul; 135(1):117-27. PubMed ID: 24310984
[TBL] [Abstract][Full Text] [Related]
14. Abnormal DNA methylation, epigenetics, and prostate cancer.
Nelson WG; Yegnasubramanian S; Agoston AT; Bastian PJ; Lee BH; Nakayama M; De Marzo AM
Front Biosci; 2007 May; 12():4254-66. PubMed ID: 17485372
[TBL] [Abstract][Full Text] [Related]
15. DNA methylation data-based molecular subtype classification related to the prognosis of patients with cervical cancer.
Li C; Ke J; Liu J; Su J
J Cell Biochem; 2020 Mar; 121(3):2713-2724. PubMed ID: 31680300
[TBL] [Abstract][Full Text] [Related]
16. Quantitative DNA methylation analysis of genes coding for kallikrein-related peptidases 6 and 10 as biomarkers for prostate cancer.
Olkhov-Mitsel E; Van der Kwast T; Kron KJ; Ozcelik H; Briollais L; Massey C; Recker F; Kwiatkowski M; Fleshner NE; Diamandis EP; Zlotta AR; Bapat B
Epigenetics; 2012 Sep; 7(9):1037-45. PubMed ID: 22874102
[TBL] [Abstract][Full Text] [Related]
17. Clinico-epigenetic combination including quantitative methylation value of DKK3 augments survival prediction of the patient with cervical cancer.
Kang WS; Cho SB; Park JS; Lee MY; Myung SC; Kim WY; Lee SH; Kim DH; Lee EJ
J Cancer Res Clin Oncol; 2013 Jan; 139(1):97-106. PubMed ID: 22961207
[TBL] [Abstract][Full Text] [Related]
18. Prostate cancer epigenetics and its clinical implications.
Yegnasubramanian S
Asian J Androl; 2016; 18(4):549-58. PubMed ID: 27212125
[TBL] [Abstract][Full Text] [Related]
19. Prostate Cancer Epigenetics: From Basic Mechanisms to Clinical Implications.
Yegnasubramanian S; De Marzo AM; Nelson WG
Cold Spring Harb Perspect Med; 2019 Apr; 9(4):. PubMed ID: 29959132
[TBL] [Abstract][Full Text] [Related]
20. Genome-wide DNA methylation measurements in prostate tissues uncovers novel prostate cancer diagnostic biomarkers and transcription factor binding patterns.
Kirby MK; Ramaker RC; Roberts BS; Lasseigne BN; Gunther DS; Burwell TC; Davis NS; Gulzar ZG; Absher DM; Cooper SJ; Brooks JD; Myers RM
BMC Cancer; 2017 Apr; 17(1):273. PubMed ID: 28412973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
